SCHEMBL19924064

SCHEMBL19924064

Cc1c(C=O)sc2[nH]c(=O)n(CC(=O)O)c(=O)c12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA3 P42263 1/20 0.34
GRIA4 P48058 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.34
ADORA2B P29275 1/20 0.33
ALDH1A1 P00352 4/20 0.32
LMNA P02545 1/20 0.32
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31
AKR1B10 O60218 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19939894 0.85 ALDH1A1 (0.41) ALDH1A1MEN1POLBCYP2C9HPGD
SCHEMBL16637864 0.83 ALDH1A1 (0.36) ADORA2BALDH1A1LMNAERCC5FEN1
SCHEMBL14945530 0.81 GRIN2D (0.35) GRIN2DGRIN3BGRIA1GRIA2GRIA3
SCHEMBL18097521 0.80 PDE1A (0.34) ADORA2BALDH1A1LMNAERCC5FEN1
SCHEMBL19924003 0.80 ADORA2B (0.32) ADORA2BALDH1A1LMNA
SCHEMBL18096996 0.79 ADORA2B (0.31) ADORA2BALDH1A1LMNA
SCHEMBL18097424 0.79 ERCC5 (0.31) ADORA2BALDH1A1LMNAERCC5FEN1
SCHEMBL19924170 0.78 ADORA2B (0.30) ADORA2B
SCHEMBL18097476 0.78 RXFP1 (0.42) ADORA2BALDH1A1LMNAMAPTRXFP1
SCHEMBL19924678 0.78 ALDH1A1 (0.32) ADORA2BALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428083-B2 Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-10-01 US disclosed
US-20180065981-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065981-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR ADORA2A, ADORA2B, ADORA3 GRIN2D 1278/4885GRIN3B 1749/4885GRIA1 2162/4885
US-10428083-B2 Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor ADORA2A, ADORA2B, ADORA3 GRIN2D 1278/4885GRIN3B 1749/4885GRIA1 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.